+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Liraglutide"

Peptide Based Metabolic Disorder Therapeutic Market in South Africa - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in South Africa

  • Report
  • May 2026
  • 150 Pages
  • South Africa
From
Peptide Based Metabolic Disorder Therapeutic Market in South Korea - Product Thumbnail Image

Peptide Based Metabolic Disorder Therapeutic Market in South Korea

  • Report
  • May 2026
  • 150 Pages
  • South Korea
From
From
From
From
From
Asia-Pacific Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Asia-Pacific Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 97 Pages
  • Asia Pacific
From
Diabetes Drug Market Overview, 2025-30 - Product Thumbnail Image

Diabetes Drug Market Overview, 2025-30

  • Report
  • June 2025
  • 109 Pages
  • Global
From
From
From
From
Loading Indicator

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes. Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain. Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more